Corcept Therapeutics Incorporated (CORT) 10-Year Financial Performance & Capital Metrics

CORT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutCorcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.Show more

Revenue $675M +39.9%
EBITDA $138M +27.7%
Net Income $140M +31.6%
EPS (Diluted) 1.23 +30.9%
Gross Margin 98.39% -0.3%
EBITDA Margin 20.49% -8.8%
Operating Margin 20.29% -8.8%
Net Margin 20.7% -5.9%
ROE 23.56% +11.9%
ROIC 22.09% +10.9%
Debt/Equity 0.01 +3324.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 22.6%
✓FCF machine: 29.0% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.1%
✓Healthy 5Y average net margin of 25.7%

✗Weaknesses

✗Weak momentum: RS Rating 5 (bottom 5%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y38.21%

5Y17.11%

3Y22.64%

TTM17.92%

Profit (Net Income) CAGR

10Y-

5Y8.21%

3Y7.49%

TTM-25.56%

EPS CAGR

10Y-

5Y9.82%

3Y11.39%

TTM-30.16%

ROCE

10Y Avg25.81%

5Y Avg25%

3Y Avg22.93%

Latest22.51%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.73B	5.64	58.02	43.5%	9.32%		1.89%
CORTCorcept Therapeutics Incorporated	3.82B	36.35	29.55	39.94%	14.19%	16.65%	5.12%	0.01
GUTSFractyl Health, Inc. Common Stock	308.28M	2.01	-1.24	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	436.08M	1.20	-1.90	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	229.96M	2.48	-2.53			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	164.38M	1.93	-2.88	-100%		-282.97%		4.17
ALTAltimmune, Inc.	418.41M	4.01	-2.99	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	741.84M	20.69	-3.12		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	50.29M	81.32M	159.2M	251.25M	306.49M	353.87M	365.98M	401.86M	482.38M	675.04M
Revenue Growth %	0.89%	0.62%	0.96%	0.58%	0.22%	0.15%	0.03%	0.1%	0.2%	0.4%
Cost of Goods Sold+	1.36M	2.06M	3.55M	5.21M	5.5M	5.58M	5.28M	5.38M	6.48M	10.88M
COGS % of Revenue	0.03%	0.03%	0.02%	0.02%	0.02%	0.02%	0.01%	0.01%	0.01%	0.02%
Gross Profit+	48.92M	79.26M	155.65M	246.03M	300.98M	348.29M	360.7M	396.47M	475.89M	664.16M
Gross Margin %	0.97%	0.97%	0.98%	0.98%	0.98%	0.98%	0.99%	0.99%	0.99%	0.98%
Gross Profit Growth %	0.91%	0.62%	0.96%	0.58%	0.22%	0.16%	0.04%	0.1%	0.2%	0.4%
Operating Expenses+	52.37M	69.08M	102.79M	156.54M	189.38M	220.09M	236.22M	283.84M	368.61M	527.21M
OpEx % of Revenue	1.04%	0.85%	0.65%	0.62%	0.62%	0.62%	0.65%	0.71%	0.76%	0.78%
Selling, General & Admin	36.95M	45.24M	62.42M	81.29M	100.36M	105.33M	122.36M	152.85M	184.26M	280.32M
SG&A % of Revenue	0.73%	0.56%	0.39%	0.32%	0.33%	0.3%	0.33%	0.38%	0.38%	0.42%
Research & Development	15.42M	23.84M	40.38M	75.25M	89.02M	114.76M	113.86M	130.99M	184.35M	246.89M
R&D % of Revenue	0.31%	0.29%	0.25%	0.3%	0.29%	0.32%	0.31%	0.33%	0.38%	0.37%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-3.44M	10.18M	52.85M	89.5M	111.61M	128.2M	124.48M	112.63M	107.28M	136.95M
Operating Margin %	-0.07%	0.13%	0.33%	0.36%	0.36%	0.36%	0.34%	0.28%	0.22%	0.2%
Operating Income Growth %	0.88%	3.96%	4.19%	0.69%	0.25%	0.15%	-0.03%	-0.1%	-0.05%	0.28%
EBITDA+	-3.29M	10.27M	52.96M	89.73M	113.78M	130.44M	127.54M	113.89M	108.32M	138.29M
EBITDA Margin %	-0.07%	0.13%	0.33%	0.36%	0.37%	0.37%	0.35%	0.28%	0.22%	0.2%
EBITDA Growth %	0.88%	4.12%	4.16%	0.69%	0.27%	0.15%	-0.02%	-0.11%	-0.05%	0.28%
D&A (Non-Cash Add-back)	155K	87K	106K	236K	2.17M	2.24M	3.07M	1.26M	1.04M	1.34M
EBIT	-3.44M	10.07M	52.85M	89.5M	111.61M	128.2M	125.01M	112.63M	107.28M	136.95M
Net Interest Income+	-2.96M	-2.04M	-49K	2.66M	5.07M	3.4M	529K	3.56M	17.27M	24.54M
Interest Income	0	0	0	2.66M	5.07M	3.4M	529K	3.56M	17.27M	24.54M
Interest Expense	2.96M	2.04M	49K	0	0	0	0	0	0	0
Other Income/Expense	-2.96M	-2.04M	-49K	2.66M	5.07M	3.4M	529K	3.56M	17.27M	24.54M
Pretax Income+	-6.41M	8.14M	52.81M	92.15M	116.68M	131.6M	125.01M	116.19M	124.56M	161.49M
Pretax Margin %	-0.13%	0.1%	0.33%	0.37%	0.38%	0.37%	0.34%	0.29%	0.26%	0.24%
Income Tax+	0	0	-76.32M	16.74M	22.5M	25.59M	12.49M	14.77M	18.42M	20.28M
Effective Tax Rate %	1%	1%	2.45%	0.82%	0.81%	0.81%	0.9%	0.87%	0.85%	0.87%
Net Income+	-6.41M	8.14M	129.12M	75.41M	94.18M	106.01M	112.51M	101.42M	106.14M	139.73M
Net Margin %	-0.13%	0.1%	0.81%	0.3%	0.31%	0.3%	0.31%	0.25%	0.22%	0.21%
Net Income Growth %	0.8%	2.27%	14.86%	-0.42%	0.25%	0.13%	0.06%	-0.1%	0.05%	0.32%
Net Income (Continuing)	-6.41M	8.14M	129.12M	75.41M	94.18M	106.01M	112.51M	101.42M	106.14M	141.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.06	0.07	1.04	0.60	0.77	0.85	0.89	0.87	0.94	1.23
EPS Growth %	0.81%	2.17%	13.86%	-0.42%	0.28%	0.1%	0.05%	-0.02%	0.08%	0.31%
EPS (Basic)	-0.06	0.07	1.14	0.60	0.82	0.92	0.97	0.95	1.02	1.35
Diluted Shares Outstanding	106.88M	116.14M	124.52M	126.69M	122.57M	124.19M	125.96M	115.97M	111.74M	113.48M
Basic Shares Outstanding	106.8M	110.57M	113.53M	125.68M	114.35M	115.41M	115.65M	106.79M	103.56M	103.23M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	48.98M	65.69M	140.6M	240.59M	307.36M	478.5M	266.46M	499.25M	458.64M	471.6M
Cash & Short-Term Investments	40.44M	51.54M	104.03M	206.76M	275.96M	440.7M	223.53M	431.67M	368.22M	383.33M
Cash Only	40.44M	51.54M	104.03M	206.76M	31.27M	76.19M	77.62M	66.33M	135.55M	127.67M
Short-Term Investments	0	0	0	0	244.69M	364.51M	145.92M	365.34M	232.67M	255.67M
Accounts Receivable	6.22M	9.86M	28.2M	17.59M	19.93M	26.2M	29.02M	46.86M	56.82M	58.08M
Days Sales Outstanding	45.16	44.26	64.64	25.55	23.73	27.02	28.95	42.56	43	31.4
Inventory	1.68M	2.33M	8.38M	16.24M	5.42M	4.91M	4.99M	6.1M	7.73M	12.41M
Days Inventory Outstanding	451.09	413.06	860.23	1.14K	359.69	321.06	344.75	413.46	435.34	416.32
Other Current Assets	642K	1.96M	2.67M	7.74M	6.04M	6.7M	8.91M	14.62M	25.86M	8.29M
Total Non-Current Assets+	2.96M	3.06M	79.94M	71.1M	104.95M	93.23M	157.29M	84.18M	162.88M	368.95M
Property, Plant & Equipment	98K	205K	518K	655K	4.5M	4.18M	1.52M	1.78M	315K	8.01M
Fixed Asset Turnover	513.12x	396.69x	307.34x	383.58x	68.17x	84.58x	241.41x	226.27x	1531.35x	84.24x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	15.28M	0	39.35M	36.2M	112.28M	4.95M	57.18M	219.83M
Other Non-Current Assets	2.86M	2.86M	3.24M	7.79M	15.43M	21.25M	16.05M	15.99M	14.79M	10.19M
Total Assets+	51.94M	68.75M	220.54M	311.69M	412.31M	571.73M	423.76M	583.43M	621.52M	840.55M
Asset Turnover	0.97x	1.18x	0.72x	0.81x	0.74x	0.62x	0.86x	0.69x	0.78x	0.80x
Asset Growth %	0.5%	0.32%	2.21%	0.41%	0.32%	0.39%	-0.26%	0.38%	0.07%	0.35%
Total Current Liabilities+	20.88M	27.37M	29.57M	35.81M	38.84M	47.49M	47.54M	72.49M	104.5M	140.77M
Accounts Payable	1.32M	2.29M	8.58M	8.27M	7.54M	10.55M	6.91M	11.98M	17.4M	15.38M
Days Payables Outstanding	355.35	406.15	881.07	578.54	499.82	690.11	477.45	811.74	979.72	515.74
Short-Term Debt	14.96M	14.66M	0	0	1.56M	2.05M	526K	1.14M	151K	829K
Deferred Revenue (Current)	158K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	3.33M	5.72M	12.42M	17.89M	16.94M	24.75M	26.25M	43.77M	59.69M	82.65M
Current Ratio	2.35x	2.40x	4.75x	6.72x	7.91x	10.07x	5.60x	6.89x	4.39x	3.35x
Quick Ratio	2.27x	2.31x	4.47x	6.26x	7.77x	9.97x	5.50x	6.80x	4.31x	3.26x
Cash Conversion Cycle	140.9	51.17	43.8	583.79	-116.39	-342.03	-103.75	-355.72	-501.38	-68.02
Total Non-Current Liabilities+	12.56M	0	0	239K	2.29M	899K	409K	9.1M	10.31M	20.19M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.9M	501K	0	0	0	6.11M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	239K	386K	398K	409K	9.1M	10.31M	14.08M
Total Liabilities	33.44M	27.37M	29.57M	35.81M	41.13M	48.39M	47.95M	81.59M	114.81M	160.96M
Total Debt+	14.96M	14.66M	0	0	3.46M	2.55M	526K	1.14M	151K	6.94M
Net Debt	-25.47M	-36.87M	-104.03M	-206.76M	-27.81M	-73.64M	-77.09M	-65.19M	-135.4M	-120.73M
Debt / Equity	0.81x	0.35x	-	-	0.01x	0.00x	0.00x	0.00x	0.00x	0.01x
Debt / EBITDA	-	1.43x	-	-	0.03x	0.02x	0.00x	0.01x	0.00x	0.05x
Net Debt / EBITDA	-	-3.59x	-1.96x	-2.30x	-0.24x	-0.56x	-0.60x	-0.57x	-1.25x	-0.87x
Interest Coverage	-1.16x	4.99x	1078.67x	-	-	-	-	-	-	-
Total Equity+	18.5M	41.38M	190.97M	275.88M	371.18M	523.34M	375.81M	501.84M	506.7M	679.59M
Equity Growth %	6.46%	1.24%	3.62%	0.44%	0.35%	0.41%	-0.28%	0.34%	0.01%	0.34%
Book Value per Share	0.17	0.36	1.53	2.18	3.03	4.21	2.98	4.33	4.53	5.99
Total Shareholders' Equity	18.5M	41.38M	190.97M	275.88M	371.18M	523.34M	375.81M	501.84M	506.7M	679.59M
Common Stock	110K	113K	115K	117K	120K	122K	127K	131K	133K	136K
Retained Earnings	-330.41M	-322.27M	-193.15M	-117.74M	-23.55M	82.46M	194.97M	296.39M	402.53M	543.74M
Treasury Stock	0	0	0	-23.66M	-62.7M	-75.8M	-410.41M	-456.15M	-635.08M	-696.17M
Accumulated OCI	-365K	-452K	-75K	-70K	261K	415K	-227K	-869K	609K	-217K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	3.13M	18.39M	60.94M	115.67M	136.12M	151.97M	167.89M	120.32M	127.04M	198.07M
Operating CF Margin %	0.06%	0.23%	0.38%	0.46%	0.44%	0.43%	0.46%	0.3%	0.26%	0.29%
Operating CF Growth %	1.11%	4.88%	2.31%	0.9%	0.18%	0.12%	0.1%	-0.28%	0.06%	0.56%
Net Income	-6.41M	8.14M	129.12M	75.41M	94.18M	106.01M	112.51M	101.42M	106.14M	141.21M
Depreciation & Amortization	155K	87K	106K	236K	2.17M	2.24M	3.07M	3.45M	2.36M	1.34M
Stock-Based Compensation	6.01M	7.06M	13.36M	23.75M	29.31M	33.54M	42.93M	42.44M	48.94M	61.35M
Deferred Taxes	0	0	-76.7M	14.07M	16.88M	14.09M	4.35M	-33.91M	-29.49M	-40.19M
Other Non-Cash Items	2.87M	1.95M	763K	-1.72M	-1.74M	1.45M	5.09M	1.38M	-9.13M	-10.94M
Working Capital Changes	500K	1.16M	-5.71M	3.93M	-4.69M	-5.36M	-57K	5.54M	8.22M	45.3M
Change in Receivables	-2.89M	-3.64M	-5.44M	-2.29M	-2.34M	-6.27M	-1.43M	-17.43M	-10.07M	1.15M
Change in Inventory	815K	-682K	-2.26M	-7.78M	-1.04M	-3.51M	3.44M	1.2M	1.26M	305K
Change in Payables	-561K	965K	6.29M	-389K	-735K	3.16M	-3.6M	4.76M	5.78M	-2.25M
Cash from Investing+	-17K	-194K	-73.46M	-90.77M	-117.83M	-119.26M	136.13M	-114.33M	90.91M	-177.6M
Capital Expenditures	-17K	-194K	-419K	-298K	-1.09M	-1.24M	-469K	-413K	-139K	-2.17M
CapEx % of Revenue	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-73.04M	-90.47M	-116.74M	-118.03M	136.59M	0	0	0
Cash from Financing+	13.07M	-7.1M	-7.95M	-14.34M	-28.64M	12.21M	-302.59M	-17.28M	-148.72M	-28.35M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	22.28M	7.68M	7.18M	9.32M	2.33M	22.16M	-6.61M	-17.28M	-3.29M	-22.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	3.11M	18.2M	60.52M	115.37M	135.03M	150.73M	167.42M	119.91M	126.9M	195.9M
FCF Margin %	0.06%	0.22%	0.38%	0.46%	0.44%	0.43%	0.46%	0.3%	0.26%	0.29%
FCF Growth %	1.11%	4.85%	2.33%	0.91%	0.17%	0.12%	0.11%	-0.28%	0.06%	0.54%
FCF per Share	0.03	0.16	0.49	0.91	1.10	1.21	1.33	1.03	1.14	1.73
FCF Conversion (FCF/Net Income)	-0.49x	2.26x	0.47x	1.53x	1.45x	1.43x	1.49x	1.19x	1.20x	1.42x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	57K	40K	377K	1.35M	6.74M	10.86M	9.1M	39.75M	47.6M	60.27M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-84.82%	27.19%	111.15%	32.31%	29.11%	23.7%	25.03%	23.11%	21.05%	23.56%
Return on Invested Capital (ROIC)	-	-	86.69%	86.02%	40.58%	24.25%	24.95%	22.97%	19.92%	22.09%
Gross Margin	97.29%	97.47%	97.77%	97.92%	98.2%	98.42%	98.56%	98.66%	98.66%	98.39%
Net Margin	-12.74%	10.01%	81.11%	30.01%	30.73%	29.96%	30.74%	25.24%	22%	20.7%
Debt / Equity	0.81x	0.35x	-	-	0.01x	0.00x	0.00x	0.00x	0.00x	0.01x
Interest Coverage	-1.16x	4.99x	1078.67x	-	-	-	-	-	-	-
FCF Conversion	-0.49x	2.26x	0.47x	1.53x	1.45x	1.43x	1.49x	1.19x	1.20x	1.42x
Revenue Growth	89.39%	61.72%	95.77%	57.82%	21.99%	15.46%	3.42%	9.8%	20.04%	39.94%

Frequently Asked Questions

Valuation & Price

Corcept Therapeutics Incorporated (CORT) has a price-to-earnings (P/E) ratio of 29.6x. This suggests investors expect higher future growth.

Growth & Financials

Corcept Therapeutics Incorporated (CORT) reported $741.2M in revenue for fiscal year 2024.

Corcept Therapeutics Incorporated (CORT) grew revenue by 39.9% over the past year. This is strong growth.

Yes, Corcept Therapeutics Incorporated (CORT) is profitable, generating $105.2M in net income for fiscal year 2024 (20.7% net margin).

Dividend & Returns

Corcept Therapeutics Incorporated (CORT) has a return on equity (ROE) of 23.6%. This is excellent, indicating efficient use of shareholder capital.

Corcept Therapeutics Incorporated (CORT) generated $162.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Corcept Therapeutics Incorporated (CORT) 10-Year Financial Performance & Capital Metrics

CORT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

Revenue $675M +39.9%
EBITDA $138M +27.7%
Net Income $140M +31.6%
EPS (Diluted) 1.23 +30.9%
Gross Margin 98.39% -0.3%
EBITDA Margin 20.49% -8.8%
Operating Margin 20.29% -8.8%
Net Margin 20.7% -5.9%
ROE 23.56% +11.9%
ROIC 22.09% +10.9%
Debt/Equity 0.01 +3324.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 22.6%
✓FCF machine: 29.0% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.1%
✓Healthy 5Y average net margin of 25.7%

✗Weaknesses

✗Weak momentum: RS Rating 5 (bottom 5%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y38.21%

5Y17.11%

3Y22.64%

TTM17.92%

Profit (Net Income) CAGR

10Y-

5Y8.21%

3Y7.49%

TTM-25.56%

EPS CAGR

10Y-

5Y9.82%

3Y11.39%

TTM-30.16%

ROCE

10Y Avg25.81%

5Y Avg25%

3Y Avg22.93%

Latest22.51%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.73B	5.64	58.02	43.5%	9.32%		1.89%
CORTCorcept Therapeutics Incorporated	3.82B	36.35	29.55	39.94%	14.19%	16.65%	5.12%	0.01
GUTSFractyl Health, Inc. Common Stock	308.28M	2.01	-1.24	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	436.08M	1.20	-1.90	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	229.96M	2.48	-2.53			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	164.38M	1.93	-2.88	-100%		-282.97%		4.17
ALTAltimmune, Inc.	418.41M	4.01	-2.99	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	741.84M	20.69	-3.12		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	50.29M	81.32M	159.2M	251.25M	306.49M	353.87M	365.98M	401.86M	482.38M	675.04M
Revenue Growth %	0.89%	0.62%	0.96%	0.58%	0.22%	0.15%	0.03%	0.1%	0.2%	0.4%
Cost of Goods Sold+	1.36M	2.06M	3.55M	5.21M	5.5M	5.58M	5.28M	5.38M	6.48M	10.88M
COGS % of Revenue	0.03%	0.03%	0.02%	0.02%	0.02%	0.02%	0.01%	0.01%	0.01%	0.02%
Gross Profit+	48.92M	79.26M	155.65M	246.03M	300.98M	348.29M	360.7M	396.47M	475.89M	664.16M
Gross Margin %	0.97%	0.97%	0.98%	0.98%	0.98%	0.98%	0.99%	0.99%	0.99%	0.98%
Gross Profit Growth %	0.91%	0.62%	0.96%	0.58%	0.22%	0.16%	0.04%	0.1%	0.2%	0.4%
Operating Expenses+	52.37M	69.08M	102.79M	156.54M	189.38M	220.09M	236.22M	283.84M	368.61M	527.21M
OpEx % of Revenue	1.04%	0.85%	0.65%	0.62%	0.62%	0.62%	0.65%	0.71%	0.76%	0.78%
Selling, General & Admin	36.95M	45.24M	62.42M	81.29M	100.36M	105.33M	122.36M	152.85M	184.26M	280.32M
SG&A % of Revenue	0.73%	0.56%	0.39%	0.32%	0.33%	0.3%	0.33%	0.38%	0.38%	0.42%
Research & Development	15.42M	23.84M	40.38M	75.25M	89.02M	114.76M	113.86M	130.99M	184.35M	246.89M
R&D % of Revenue	0.31%	0.29%	0.25%	0.3%	0.29%	0.32%	0.31%	0.33%	0.38%	0.37%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-3.44M	10.18M	52.85M	89.5M	111.61M	128.2M	124.48M	112.63M	107.28M	136.95M
Operating Margin %	-0.07%	0.13%	0.33%	0.36%	0.36%	0.36%	0.34%	0.28%	0.22%	0.2%
Operating Income Growth %	0.88%	3.96%	4.19%	0.69%	0.25%	0.15%	-0.03%	-0.1%	-0.05%	0.28%
EBITDA+	-3.29M	10.27M	52.96M	89.73M	113.78M	130.44M	127.54M	113.89M	108.32M	138.29M
EBITDA Margin %	-0.07%	0.13%	0.33%	0.36%	0.37%	0.37%	0.35%	0.28%	0.22%	0.2%
EBITDA Growth %	0.88%	4.12%	4.16%	0.69%	0.27%	0.15%	-0.02%	-0.11%	-0.05%	0.28%
D&A (Non-Cash Add-back)	155K	87K	106K	236K	2.17M	2.24M	3.07M	1.26M	1.04M	1.34M
EBIT	-3.44M	10.07M	52.85M	89.5M	111.61M	128.2M	125.01M	112.63M	107.28M	136.95M
Net Interest Income+	-2.96M	-2.04M	-49K	2.66M	5.07M	3.4M	529K	3.56M	17.27M	24.54M
Interest Income	0	0	0	2.66M	5.07M	3.4M	529K	3.56M	17.27M	24.54M
Interest Expense	2.96M	2.04M	49K	0	0	0	0	0	0	0
Other Income/Expense	-2.96M	-2.04M	-49K	2.66M	5.07M	3.4M	529K	3.56M	17.27M	24.54M
Pretax Income+	-6.41M	8.14M	52.81M	92.15M	116.68M	131.6M	125.01M	116.19M	124.56M	161.49M
Pretax Margin %	-0.13%	0.1%	0.33%	0.37%	0.38%	0.37%	0.34%	0.29%	0.26%	0.24%
Income Tax+	0	0	-76.32M	16.74M	22.5M	25.59M	12.49M	14.77M	18.42M	20.28M
Effective Tax Rate %	1%	1%	2.45%	0.82%	0.81%	0.81%	0.9%	0.87%	0.85%	0.87%
Net Income+	-6.41M	8.14M	129.12M	75.41M	94.18M	106.01M	112.51M	101.42M	106.14M	139.73M
Net Margin %	-0.13%	0.1%	0.81%	0.3%	0.31%	0.3%	0.31%	0.25%	0.22%	0.21%
Net Income Growth %	0.8%	2.27%	14.86%	-0.42%	0.25%	0.13%	0.06%	-0.1%	0.05%	0.32%
Net Income (Continuing)	-6.41M	8.14M	129.12M	75.41M	94.18M	106.01M	112.51M	101.42M	106.14M	141.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.06	0.07	1.04	0.60	0.77	0.85	0.89	0.87	0.94	1.23
EPS Growth %	0.81%	2.17%	13.86%	-0.42%	0.28%	0.1%	0.05%	-0.02%	0.08%	0.31%
EPS (Basic)	-0.06	0.07	1.14	0.60	0.82	0.92	0.97	0.95	1.02	1.35
Diluted Shares Outstanding	106.88M	116.14M	124.52M	126.69M	122.57M	124.19M	125.96M	115.97M	111.74M	113.48M
Basic Shares Outstanding	106.8M	110.57M	113.53M	125.68M	114.35M	115.41M	115.65M	106.79M	103.56M	103.23M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	48.98M	65.69M	140.6M	240.59M	307.36M	478.5M	266.46M	499.25M	458.64M	471.6M
Cash & Short-Term Investments	40.44M	51.54M	104.03M	206.76M	275.96M	440.7M	223.53M	431.67M	368.22M	383.33M
Cash Only	40.44M	51.54M	104.03M	206.76M	31.27M	76.19M	77.62M	66.33M	135.55M	127.67M
Short-Term Investments	0	0	0	0	244.69M	364.51M	145.92M	365.34M	232.67M	255.67M
Accounts Receivable	6.22M	9.86M	28.2M	17.59M	19.93M	26.2M	29.02M	46.86M	56.82M	58.08M
Days Sales Outstanding	45.16	44.26	64.64	25.55	23.73	27.02	28.95	42.56	43	31.4
Inventory	1.68M	2.33M	8.38M	16.24M	5.42M	4.91M	4.99M	6.1M	7.73M	12.41M
Days Inventory Outstanding	451.09	413.06	860.23	1.14K	359.69	321.06	344.75	413.46	435.34	416.32
Other Current Assets	642K	1.96M	2.67M	7.74M	6.04M	6.7M	8.91M	14.62M	25.86M	8.29M
Total Non-Current Assets+	2.96M	3.06M	79.94M	71.1M	104.95M	93.23M	157.29M	84.18M	162.88M	368.95M
Property, Plant & Equipment	98K	205K	518K	655K	4.5M	4.18M	1.52M	1.78M	315K	8.01M
Fixed Asset Turnover	513.12x	396.69x	307.34x	383.58x	68.17x	84.58x	241.41x	226.27x	1531.35x	84.24x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	15.28M	0	39.35M	36.2M	112.28M	4.95M	57.18M	219.83M
Other Non-Current Assets	2.86M	2.86M	3.24M	7.79M	15.43M	21.25M	16.05M	15.99M	14.79M	10.19M
Total Assets+	51.94M	68.75M	220.54M	311.69M	412.31M	571.73M	423.76M	583.43M	621.52M	840.55M
Asset Turnover	0.97x	1.18x	0.72x	0.81x	0.74x	0.62x	0.86x	0.69x	0.78x	0.80x
Asset Growth %	0.5%	0.32%	2.21%	0.41%	0.32%	0.39%	-0.26%	0.38%	0.07%	0.35%
Total Current Liabilities+	20.88M	27.37M	29.57M	35.81M	38.84M	47.49M	47.54M	72.49M	104.5M	140.77M
Accounts Payable	1.32M	2.29M	8.58M	8.27M	7.54M	10.55M	6.91M	11.98M	17.4M	15.38M
Days Payables Outstanding	355.35	406.15	881.07	578.54	499.82	690.11	477.45	811.74	979.72	515.74
Short-Term Debt	14.96M	14.66M	0	0	1.56M	2.05M	526K	1.14M	151K	829K
Deferred Revenue (Current)	158K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	3.33M	5.72M	12.42M	17.89M	16.94M	24.75M	26.25M	43.77M	59.69M	82.65M
Current Ratio	2.35x	2.40x	4.75x	6.72x	7.91x	10.07x	5.60x	6.89x	4.39x	3.35x
Quick Ratio	2.27x	2.31x	4.47x	6.26x	7.77x	9.97x	5.50x	6.80x	4.31x	3.26x
Cash Conversion Cycle	140.9	51.17	43.8	583.79	-116.39	-342.03	-103.75	-355.72	-501.38	-68.02
Total Non-Current Liabilities+	12.56M	0	0	239K	2.29M	899K	409K	9.1M	10.31M	20.19M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.9M	501K	0	0	0	6.11M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	239K	386K	398K	409K	9.1M	10.31M	14.08M
Total Liabilities	33.44M	27.37M	29.57M	35.81M	41.13M	48.39M	47.95M	81.59M	114.81M	160.96M
Total Debt+	14.96M	14.66M	0	0	3.46M	2.55M	526K	1.14M	151K	6.94M
Net Debt	-25.47M	-36.87M	-104.03M	-206.76M	-27.81M	-73.64M	-77.09M	-65.19M	-135.4M	-120.73M
Debt / Equity	0.81x	0.35x	-	-	0.01x	0.00x	0.00x	0.00x	0.00x	0.01x
Debt / EBITDA	-	1.43x	-	-	0.03x	0.02x	0.00x	0.01x	0.00x	0.05x
Net Debt / EBITDA	-	-3.59x	-1.96x	-2.30x	-0.24x	-0.56x	-0.60x	-0.57x	-1.25x	-0.87x
Interest Coverage	-1.16x	4.99x	1078.67x	-	-	-	-	-	-	-
Total Equity+	18.5M	41.38M	190.97M	275.88M	371.18M	523.34M	375.81M	501.84M	506.7M	679.59M
Equity Growth %	6.46%	1.24%	3.62%	0.44%	0.35%	0.41%	-0.28%	0.34%	0.01%	0.34%
Book Value per Share	0.17	0.36	1.53	2.18	3.03	4.21	2.98	4.33	4.53	5.99
Total Shareholders' Equity	18.5M	41.38M	190.97M	275.88M	371.18M	523.34M	375.81M	501.84M	506.7M	679.59M
Common Stock	110K	113K	115K	117K	120K	122K	127K	131K	133K	136K
Retained Earnings	-330.41M	-322.27M	-193.15M	-117.74M	-23.55M	82.46M	194.97M	296.39M	402.53M	543.74M
Treasury Stock	0	0	0	-23.66M	-62.7M	-75.8M	-410.41M	-456.15M	-635.08M	-696.17M
Accumulated OCI	-365K	-452K	-75K	-70K	261K	415K	-227K	-869K	609K	-217K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	3.13M	18.39M	60.94M	115.67M	136.12M	151.97M	167.89M	120.32M	127.04M	198.07M
Operating CF Margin %	0.06%	0.23%	0.38%	0.46%	0.44%	0.43%	0.46%	0.3%	0.26%	0.29%
Operating CF Growth %	1.11%	4.88%	2.31%	0.9%	0.18%	0.12%	0.1%	-0.28%	0.06%	0.56%
Net Income	-6.41M	8.14M	129.12M	75.41M	94.18M	106.01M	112.51M	101.42M	106.14M	141.21M
Depreciation & Amortization	155K	87K	106K	236K	2.17M	2.24M	3.07M	3.45M	2.36M	1.34M
Stock-Based Compensation	6.01M	7.06M	13.36M	23.75M	29.31M	33.54M	42.93M	42.44M	48.94M	61.35M
Deferred Taxes	0	0	-76.7M	14.07M	16.88M	14.09M	4.35M	-33.91M	-29.49M	-40.19M
Other Non-Cash Items	2.87M	1.95M	763K	-1.72M	-1.74M	1.45M	5.09M	1.38M	-9.13M	-10.94M
Working Capital Changes	500K	1.16M	-5.71M	3.93M	-4.69M	-5.36M	-57K	5.54M	8.22M	45.3M
Change in Receivables	-2.89M	-3.64M	-5.44M	-2.29M	-2.34M	-6.27M	-1.43M	-17.43M	-10.07M	1.15M
Change in Inventory	815K	-682K	-2.26M	-7.78M	-1.04M	-3.51M	3.44M	1.2M	1.26M	305K
Change in Payables	-561K	965K	6.29M	-389K	-735K	3.16M	-3.6M	4.76M	5.78M	-2.25M
Cash from Investing+	-17K	-194K	-73.46M	-90.77M	-117.83M	-119.26M	136.13M	-114.33M	90.91M	-177.6M
Capital Expenditures	-17K	-194K	-419K	-298K	-1.09M	-1.24M	-469K	-413K	-139K	-2.17M
CapEx % of Revenue	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-73.04M	-90.47M	-116.74M	-118.03M	136.59M	0	0	0
Cash from Financing+	13.07M	-7.1M	-7.95M	-14.34M	-28.64M	12.21M	-302.59M	-17.28M	-148.72M	-28.35M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	22.28M	7.68M	7.18M	9.32M	2.33M	22.16M	-6.61M	-17.28M	-3.29M	-22.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	3.11M	18.2M	60.52M	115.37M	135.03M	150.73M	167.42M	119.91M	126.9M	195.9M
FCF Margin %	0.06%	0.22%	0.38%	0.46%	0.44%	0.43%	0.46%	0.3%	0.26%	0.29%
FCF Growth %	1.11%	4.85%	2.33%	0.91%	0.17%	0.12%	0.11%	-0.28%	0.06%	0.54%
FCF per Share	0.03	0.16	0.49	0.91	1.10	1.21	1.33	1.03	1.14	1.73
FCF Conversion (FCF/Net Income)	-0.49x	2.26x	0.47x	1.53x	1.45x	1.43x	1.49x	1.19x	1.20x	1.42x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	57K	40K	377K	1.35M	6.74M	10.86M	9.1M	39.75M	47.6M	60.27M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-84.82%	27.19%	111.15%	32.31%	29.11%	23.7%	25.03%	23.11%	21.05%	23.56%
Return on Invested Capital (ROIC)	-	-	86.69%	86.02%	40.58%	24.25%	24.95%	22.97%	19.92%	22.09%
Gross Margin	97.29%	97.47%	97.77%	97.92%	98.2%	98.42%	98.56%	98.66%	98.66%	98.39%
Net Margin	-12.74%	10.01%	81.11%	30.01%	30.73%	29.96%	30.74%	25.24%	22%	20.7%
Debt / Equity	0.81x	0.35x	-	-	0.01x	0.00x	0.00x	0.00x	0.00x	0.01x
Interest Coverage	-1.16x	4.99x	1078.67x	-	-	-	-	-	-	-
FCF Conversion	-0.49x	2.26x	0.47x	1.53x	1.45x	1.43x	1.49x	1.19x	1.20x	1.42x
Revenue Growth	89.39%	61.72%	95.77%	57.82%	21.99%	15.46%	3.42%	9.8%	20.04%	39.94%

Frequently Asked Questions

Valuation & Price

Corcept Therapeutics Incorporated (CORT) has a price-to-earnings (P/E) ratio of 29.6x. This suggests investors expect higher future growth.

Growth & Financials

Corcept Therapeutics Incorporated (CORT) reported $741.2M in revenue for fiscal year 2024.

Corcept Therapeutics Incorporated (CORT) grew revenue by 39.9% over the past year. This is strong growth.

Yes, Corcept Therapeutics Incorporated (CORT) is profitable, generating $105.2M in net income for fiscal year 2024 (20.7% net margin).

Dividend & Returns

Corcept Therapeutics Incorporated (CORT) has a return on equity (ROE) of 23.6%. This is excellent, indicating efficient use of shareholder capital.

Corcept Therapeutics Incorporated (CORT) generated $162.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.